CureVac B.V

CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). Its product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and protein therapy. The company was founded by Ingmar Hoerr and Florian von der Mülbe in 2000 and is headquartered in Tübingen, Germany.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna

Two promising biotechs with COVID-19 vaccine candidates in development. One of them is the more likely winner.

Better Coronavirus Stock: CureVac vs. Moderna

Tiny CureVac, which popped in its IPO on Friday, announced Thursday it's close to inking a big contract with the European Commission for its coronavirus vaccine candidate. CVAC stock jumped.

Hot Biotech IPO Latest To Gain In Coronavirus Vaccine Race

AstraZeneca

BioNTech SE

Inovio Pharmaceuticals

Novavax

Pfizer

Hope for a successful vaccine by the winter is fueling trials at a record pace.

COVID-19: The Real Results Are A Long Way Away

But it's also behind both Inovio and Novavax in the race to develop a coronavirus vaccine.

Meet the Hot New Coronavirus Vaccine Stock That's Already Bigger Than Inovio and Novavax

I describe that value as astonishing because the company recorded revenues of $3.1 million, down slightly year-on-year, in its most recently reported quarter, ending March 31st.

CureVac Is Incredibly Overvalued And Perfectly Captures The Insanity Of The U.S. Stock Market In 2020

Sorrento Therapeutics Inc

Consider the risks before taking any chances with these clinical-stage drugmakers.

2 Ultra-Risky Biotech Stocks That Could Make You Filthy Rich

CureVac N.V. (NASDAQ: CVAC) shares have been on a tear ever since it debuted on Wall Street Friday.

The COVID-19 News Sending Newly Listed CureVac Shares Higher

It would be a gross understatement to say that investors who got in at CureVac's (NASDAQ:CVAC) initial public offering price had a good start to their weekend.

CureVac Shares Nearly Triple on Opening Day

Four IPOs and six SPACs entered the public markets this past week led by CureVac, which posted the largest first-day pop for a US IPO since 2005.

U.S. IPO Weekly Recap: Coronavirus Vaccine Developer CureVac Pops 249% In A 4-IPO Week

Shares of German biotechnology firm CureVac nearly tripled in their Nasdaq debut Friday, marking the first stock market debut of a company developing a potential vaccine to combat the novel coronavirus. The stock opened at $44 per share, up from the initial public offering price of $16 per share.

Bill Gates-backed vaccine maker CureVac shares nearly triple in Nasdaq debut

German biotech firm CureVac (NASDAQ: CVAC) opened for trading on Friday. CureVac listed on the Nasdaq under the symbol CVAC.

What To Know About The CureVac IPO

The CureVac (CVAC) IPO is underway Friday and potential investors will want to keep an eye on the stock as it's seeing massive gains.

CureVac IPO: 13 Things for Potential CVAC Stock Investors to Know

CureVac B.V. (NASDAQ: CVAC) wasn’t the only initial public offering making some noise in the markets on Friday, but the stock exploded into the market, more than double its original pricing.

CureVac Enters the Market With a Bang

Shares of German biotechnology firm CureVac BV nearly tripled in their Nasdaq debut on Friday, marking the first stock market debut of a company developing a potential vaccine to combat the coronavirus.

Coronavirus vaccine developer CureVac shares surge 175% in Nasdaq debut

Shares of CureVac BV CVAC, +162.43% blasted off in their public debut Friday, as they opened at nearly triple the $16 initial public offering price.

CureVac's stock debuts at nearly triple the IPO price

CureVac raised $213 million in its initial public offering in New York on Thursday, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the coronavirus.

Coronavirus vaccine developer CureVac raises $213 million in IPO

CureVac BV, a clinical-stage biotech headquartered in Germany, priced its initial public offering on Friday at $16 a share, the high end of its proposed range.

CureVac raises $213.3 million in IPO after pricing at $16 a share, high end of proposed range

CureVac BV raised $213 million in its initial public offering on Thursday, a person familiar with the matter said, setting the stage for the first stock market debut of a company developing a promising vaccine to combat the novel coronavirus.

News for CureVac B.V Stock (CVAC)